Treatment modifications/dosing delays and the factors predicating treatment modification should be explicit and clear. If dose
Dosing & Dose Management – TAGRISSO® (osimertinib)
Dose Modification for Myelosuppression
How to Dose Modify | REVLIMID® (lenalidomide) for MDS
Dosing for Jakafi in Myelofibrosis | Jakafi HCP
ARV Dosing: Renal Impairment — EACS
Dosing & Administration – gBRCAm, HER2-Negative Metastatic Breast Cancer – LYNPARZA® (olaparib)
KISQALI® (ribociclib) Dosing & Administration | HCP
ALECENSA® (alectinib) Dose Modifications
IMBRUVICA® (ibrutinib) Dosing Modifications for CLL | HCP
Dose Modifications | REVLIMID® (lenalidomide) for MCL
COTELLIC® (cobimetinib) + ZELBORAF® (vemurafenib) Dose Modification for HCPs
Dosing & Administration - Dose Modification & Toxicity Management | Aliqopa US HCP
Dose modification of cisplatin in renal impairment | Download Table
IBRANCE® (palbociclib) Recommended Dose Modifications | Safety Info
Dose Modifications for Adverse Reactions to KEYTRUDA® (pembrolizumab) | HCP
Dose Modifications in Clinical Trial | REVLIMID® (lenalidomide) for MDS
Dose Modification Guidelines | NINLARO® (ixazomib)
Dose Modifications | REVLIMID (lenalidomide) for MDS
Dose Modifications | REVLIMID® (lenalidomide) for MCL
NOVA Dosing | ZEJULA (niraparib)
Dosing and Administration | BALVERSA® (erdafitinib) HCP
Dosing for mNSCLC Treatment | CYRAMZA® (ramucirumab)
Dose modification for neutropenia or thrombocytopenia at day 8 or 15 | Download Table
LENVIMA® (lenvatinib) HCP Website | Adverse Reaction Management
Dose modification scheme for managing palbociclib/placebo-related... | Download Scientific Diagram
Dosing & Management – LYNPARZA® (olaparib)
IBRANCE® (palbociclib) Recommended Dose Modifications | Safety Info
